Blis Technologies has upgraded its full-year earnings guidance, citing favourable timing of several major orders, increased sales across its business-to-business channels and an underspend in some planned research and development expenditure this year.
The Dunedin-based probiotics company’s latest guidance to the NZX for the year ended March 31, 2024 was for revenue of $11.5 million and ebitda of $0.8m, subject to completion of the annual financial audit.
That was an increase on the previous guidance given in February of revenue of about $11m and ebitda of breakeven to $0.3m.
Last year, the company delivered revenue of $10.2m, up from $8.9m the previous year and its ebitda loss of $0.6m was down from a $2.1m loss the previous year.
